Granted Patent
B2
US 12,606,613 · App. 17/923,462 · Granted Apr 21, 2026
Humanized anti-C5a antibodies
Assignee:
InflaRx GmbH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to antibodies that specifically bind to a conformational epitope of human C5a. The invention particularly relates to humanized anti-C5a antibodies. The antibodies described herein are useful as active agents in pharmaceutical compositions. The antibodies and pharmaceutical compositions are especially useful for the treatment and prevention of diseases or disorders involving pathological C5a activity.
Claims (31)
1 . An antibody or an antigen-binding fragment thereof that specifically binds to human C5, comprising a heavy chain variable domain (VH) and a light chain variable domain (VL),
a) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 8 (VH2) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 15 (Vκ3);
b) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 8 (VH2) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 16 (Vκ4);
c) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 9 (VH3) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 14 (Vκ2);
d) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 9 (VH3) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 16 (Vκ4);
e) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 10 (VH4) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 13 (Vκ1);
f) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 10 (VH4) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 14 (Vκ2);
g) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 10 (VH4) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 15 (Vκ3);
h) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 10 (VH4) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 16 (Vκ4);
i) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 11 (VH5) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 13 (Vκ1);
j) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 11 (VH5) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 14 (Vκ2);
k) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 11 (VH5) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 15 (Vκ3); or
l) wherein said VH domain comprises or consists of the amino acid sequence according to SEQ ID NO: 11 (VH5) and the VL domain comprises or consists of the amino acid sequence according to SEQ ID NO: 16 (Vκ4).
2 . The antibody or an antigen-binding fragment thereof according to claim 1 , wherein said antibody or said antigen-binding fragment thereof comprises:
a) a VH domain comprising, essentially consisting of, or consisting of the amino acid sequence according to SEQ ID NO: 10 (VH4) and a VL domain comprising, essentially consisting of, or consisting of the amino acid sequence according to SEQ ID NO: 16 (Vκ4), or
b) a VH domain comprising, essentially consisting of, or consisting of the amino acid sequence according to SEQ ID NO: 11 (VH5) and a VL domain comprising, essentially consisting of, or consisting of the amino acid sequence according to SEQ ID NO: 15 (Vκ3).
3 . The antibody or the antigen-binding fragment thereof according to claim 1 , wherein the antibody is a humanized antibody.
4 . The antibody or an antigen-binding fragment thereof according to claim 1 , further comprising a constant domain, wherein said constant domain comprises, essentially consists of, or consists of the amino acid sequence according to SEQ ID NO: 19 (IgG4 WT constant), wherein said amino acid sequence according to SEQ ID NO: 19 optionally comprises one or more of the following amino acid exchanges:
an amino acid exchange S108P;
the amino acid exchanges T130Q and M308L; and/or
the amino acid exchanges M132Y, S134T, and T136E.
5 . The antibody or an antigen-binding fragment thereof according to claim 1 , wherein the antigen-binding fragment of an antibody is selected from the group consisting of Fab fragments, Fab′ fragments, F(ab′) 2 fragments, Fd fragments, Fv fragments, disulfide-linked Fvs (dsFv), single domain antibodies and single chain Fv (scFv) antibodies.
6 . The antibody or an antigen-binding fragment thereof according to claim 1 , wherein said antibody or said antigen-binding fragment thereof exhibits one or more of the following properties:
said antibody or said antigen-binding fragment thereof has a binding constant to C5a with a K d value of 10 nM or less;
said antibody or said antigen-binding fragment thereof exhibits at least 75% blocking activity for biological effects induced by one molecule C5a;
said antibody or said antigen-binding fragment thereof does not inhibit CH50 activity in human plasma; and/or
said antibody or said antigen-binding fragment thereof has a reduced immunogenicity as compared to IFX-1.
7 . A pharmaceutical composition comprising:
the antibody or an antigen-binding fragment thereof according to claim 3 and one or more pharmaceutically acceptable carriers, diluents, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents, and/or preservatives.
8 . A method of blocking or inhibiting C5a-stimulated CD11b upregulation on immune cells, the method comprising contacting the cells with the antibody of claim 3 , or an antigen-binding fragment thereof, or a pharmaceutically acceptable composition thereof, wherein the antibody, or an antigen binding fragment thereof, blocks or inhibits the C5a-stimulated CD11b upregulation.
9 . The method of claim 8 , wherein the immune cells are granulocytes or human granulocytes.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 31, 2025
From: GUO, RENFENG; RIEDEMANN, NIELS C.
To: INFLARX GMBH
Reel/Frame 072749/0637 →
Priority Claims (1)
EP 20173255
· May 6, 2020
· regional
Continuity (1)
References Cited (241)
US 4704355A
· Bernstein
· 1987
[cited by applicant]
US 5939598A
· Kucherlapati et al.
· 1999
[cited by applicant]
US 6355245B1
· Evans et al.
· 2002
[cited by applicant]
US 20030133939A1
· Ledbetter et al.
· 2003
[cited by applicant]
US 20040110226A1
· Lazar et al.
· 2004
[cited by applicant]
US 20230158060A1
· Riedemann et al.
· 2023
[cited by applicant]
CN 1604909A
· 2005
[cited by applicant]
CN 1847261A
· 2006
[cited by applicant]
CN 1997384A
· 2007
[cited by applicant]
CN 105392803A
· 2016
[cited by applicant]
CN 106132982A
· 2016
[cited by applicant]
CN 111108118A
· 2020
[cited by applicant]
JP 2012514465A
· 2012
[cited by applicant]
JP 2014529997A
· 2014
[cited by applicant]
JP 2015511965A
· 2015
[cited by applicant]
JP 2016518331A
· 2016
[cited by applicant]
JP 2016523829A
· 2016
[cited by applicant]
JP 2017514791A
· 2017
[cited by applicant]
WO 1991004014A1
· 1991
[cited by applicant]
WO 1999000406A1
· 1999
[cited by applicant]
WO 2001015731A1
· 2001
[cited by applicant]
WO 2003015819A1
· 2003
[cited by applicant]
WO 2003033528A1
· 2003
[cited by applicant]
WO 2005079363A2
· 2005
[cited by applicant]
WO 2005092366A1
· 2005
[cited by applicant]
WO 2006082406A2
· 2006
[cited by applicant]
WO 2008009062A1
· 2008
[cited by applicant]
WO 2008029167A1
· 2008
[cited by applicant]
WO 2010075257A1
· 2010
[cited by applicant]
WO 2010079314A2
· 2010
[cited by applicant]
WO 2011063980A1
· 2011
[cited by applicant]
WO 2011137395A1
· 2011
[cited by applicant]
WO 2011163640A1
· 2011
[cited by applicant]
WO 2013041730A1
· 2013
[cited by applicant]
WO 2013138586A1
· 2013
[cited by applicant]
WO 2014160129A2
· 2014
[cited by applicant]
WO 2014180961A1
· 2014
[cited by applicant]
WO 2015140304A1
· 2015
[cited by applicant]
WO 2016044419A1
· 2016
[cited by applicant]
WO 2016061066A1
· 2016
[cited by applicant]
WO 2016102877A1
· 2016
[cited by applicant]
WO 2016209956A1
· 2016
[cited by applicant]
WO 2017176620A2
· 2017
[cited by applicant]
WO 2017218515A1
· 2017
[cited by applicant]
WO 2018175833A1
· 2018
[cited by applicant]
WO 2018184739A1
· 2018
[cited by applicant]
WO 2018234118A1
· 2018
[cited by applicant]
WO 2020051418A1
· 2020
[cited by applicant]
WO 2020182384A1
· 2020
[cited by applicant]
WO 2020214716A1
· 2020
[cited by applicant]
WO 2021188601A1
· 2021
[cited by applicant]
WO 2021190770A1
· 2021
[cited by applicant]
WO 2021205013A1
· 2021
[cited by applicant]
WO 2021211940A1
· 2021
[cited by applicant]
Fireman B.V., inflaRx—Final Pursuant to 424(b)(a). pp. 1-229, Nov. 7, 2017 (Year: 2017).
[cited by examiner]
Inflarx—BDB contract. pp. 1-38, 2015. (Year: 2015).
[cited by examiner]
OfficeActiondatedNov. 11, 2025,incorrespondingKoreanPatentApplicationNo. 10-2022-7033905(9pages). English Translation. (Year: 2025).
[cited by examiner]
Wang et al., “The role of C5a in acute lung injury induced by highly pathogenic viral infections,” Emerging Microbes & Infections, 2015, vol. 4, e28, pp. 1-7.
[cited by applicant]
Weiss et al., “Rapid mapping of protein functional epitopes by combinatorial alanine scanning,” Proceedings of the National Academy of Sciences, Aug. 1, 2000, vol. 97, No. 16, pp. 8950-8954.
[cited by applicant]
Werfel et al., “C5a receptors are detectable on mast cells in normal human skin and in psoriatic plaques but not in weal and flare reactions or in urticaria pigmentosa by immunohistochemistry,” Archives of Dermatologica…
[cited by applicant]
Wills-Karp, Marsha, “Complement Activation Pathways: A Bridge between Innate and Adaptive Immune Responses in Asthma,” Proceedings of the American Thoracic Society, 2007, vol. 4, pp. 247-251.
[cited by applicant]
Wollina et al., “Acne inversa (Hidradenitis suppurativa): A review with a focus on pathogenesis and treatment,” Indian Dermatology Online Journal, Jan.-Mar. 2013, vol. 4, No. 1, pp. 2-11.
[cited by applicant]
Xu et al., “Complement C5a regulates IL-17 by affecting the crosstalk between DC and γδ T cells in CLP-induced sepsis,” European Journal of Immunology, 2010, vol. 40, No. 4, pp. 1079-1088.
[cited by applicant]
Zhang et al., “Antibody Responses Against SARS Coronavirus Are Correlated With Disease Outcome of Infected Individuals,” Journal of Medical Virology, 2006, vol. 78, pp. 1-8.
[cited by applicant]
Office Action dated Apr. 23, 2024 in corresponding Japanese Patent Application No. 2022-567241 (6 pages).
[cited by applicant]
English translation of Office Action dated Apr. 23, 2024 in corresponding Japanese Patent Application No. 2022-567241 (5 pages).
[cited by applicant]
Gueler et al., “Complement 5a Receptor Inhibition Improves Renal Allografl Survival,” Journal of the American Society of Nephrology, 2008, vol. 19, pp. 2302-2312.
[cited by applicant]
Guo et al., “Divergent Signaling Pathways in Phagocytic Cells during Sepsis,” The Journal of Immunology, 2006, vol. 177, No. 2, pp. 1306-1313.
[cited by applicant]
Guo et al., “IFX-1 blocking the anaphylatoxin C5a—an anti-inflammatory effect in patients with hidradenitis suppurativa,” Aug. 29, 2017, poster (1 page).
[cited by applicant]
Harding, J., “Eculizumab,” Drugs of the Future, 2004, vol. 29, No. 7, pp. 673-676.
[cited by applicant]
Höpken et al., “Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies,” European Journal of Immunology, 1996, vol. 26, pp. 1103-1109.
[cited by applicant]
Howard III et al., “Intracerebral drug delivery in rats with lesion-induced memory deficits,” Journal of Neurosurgery, Jul. 1989, vol. 71, pp. 105-112.
[cited by applicant]
Huber-Lang et al., “Protective effects of anti-C5a peptide antibodies in experimental sepsis,” The FASEB Journal, Jan. 19, 2001, vol. 15, No. 3, pp. 568-570.
[cited by applicant]
Hycult Biotech Catalog, “Complement and Collectins,” 2020-2021, Uden, The Netherlands, pp. 1-8.
[cited by applicant]
Hyzewicz et al., “Low-Intensity Training and the C5a Complement Antagonist NOX-D21 Rescue the mdx Phenotype through Modulation of Inflammation,” The American Journal of Pathology, May 2017, vol. 187, No. 5, pp. 1147-116…
[cited by applicant]
Imagawa et al., “Consequences of cell membrane attack by complement: Release of arachidonate and formation of inflammatory derivatives,” Proceedings of the National Academy of Sciences of the United States of America, N…
[cited by applicant]
InflaRx, “InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa,” Nov. 6, 2019, pp. 1-8.
[cited by applicant]
InflaRx, “InflaRx initiates exploratory Phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa,” Jan. 4, 2017, pp. 1-2.
[cited by applicant]
InflaRx, “InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa,” Jul. 18, 2019, pp. 1-9.
[cited by applicant]
Jayne et al., “Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis,” Journal of the American Society of Nephrology, 2017, vol. 28, pp. 2756-2767.
[cited by applicant]
Jemec et al., “The prevalence of hidradenitis suppurativa and its potential precursor lesions,” Journal of the American Academy of Dermatology, Aug. 1996, vol. 35, No. 2, Pl. 1, pp. 191-194.
[cited by applicant]
Jemec, Gregor B.E., “Medical treatment of hidradenitis suppurativa,” Expert Opinion on Pharmacotherapy, 2004, vol. 5, No. 8, pp. 1767-1770.
[cited by applicant]
Jiang et al., “Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV,” Emerging Microbes & Infections, 2018, vol. 7, Article No. 77, pp. 1-12.
[cited by applicant]
Jorizzo et al., “Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: Cutaneous polyarteritis nodosa and Behçet's disease,” Journal of the American Academy of Dermatology, Jun. 1991, vol. 24, No. 6,…
[cited by applicant]
Kaplan, M., “Eculizumab,” Current Opinion in Investigational Drugs, 2002, vol. 3, No. 7, pp. 1017-1023.
[cited by applicant]
Kaplan, Mariana J., “Role of neutrophils in systemic autoimmune diseases,” Arthritis Research & Therapy, 2013, vol. 15, Article No. 219, pp. 1-9.
[cited by applicant]
Keseroglu et al., “A Case of Subcorneal Pustular Dermatosis Successfully Treated with Acitretin,” Archives of Inflammation, Oct. 27, 2016, vol. 1, No. 2, pp. 1-3.
[cited by applicant]
Khameneh et al., “C5a regulates IL-1β production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis,” Frontiers in Pharmacology, Jan. 23, 2017, vol. 8, Article 10, pp. 1-11.
[cited by applicant]
Kimball et al., “Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment,” British Journal of D…
[cited by applicant]
Klos et al., “International Union of Basic and Clinical Pharmacology [corrected]. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors,” Pharmacological Reviews, Jan. 2013, vol. 65, pp. 500-543.
[cited by applicant]
Klos et al., “The role of the anaphylatoxins in health and disease,” Molecular Immunology, 2009, vol. 46, pp. 2753-2766.
[cited by applicant]
Kurzen et al., “Whal causes hidradenitis suppuraliva?” Experimental Dermatology, 2008, vol. 17, No. 5, pp. 455-456.
[cited by applicant]
Kussie et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” Journal of Immunology, 1994, vol. 152, pp. 146-152.
[cited by applicant]
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” Journal of Macromolecular Science, Reviews in Macromolecular Chemistry and Physics, 1983, vo…
[cited by applicant]
Langer, Robert, “New Methods of Drug Delivery,” Science, Sep. 28, 1990, vol. 249, pp. 1527-1533.
[cited by applicant]
Li et al., “Melformin reduces diabetes-related inflammatory molecules in human vitreous and retinal vascular endolhelial cells,” Investigative Ophthalmology & Visual Science, Sep. 2016, vol. 57, p. 6346; abstract submit…
[cited by applicant]
Li et al., “Neuroprotective effects of argalroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage,” Clinical and Experimental Immunology, 2014, vol. 175, No. 2, pp. 285-295.
[cited by applicant]
Lima et al., “Keralinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa,” British Journal of Dermatology, 2016, vol. 174, pp. 514-521.
[cited by applicant]
March et al., “Potent Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear Leukocytes. Relationships between Structures and Activity,” Molecular Pharmacology, 2004, vol. 65, No. 4, pp. 868-879.
[cited by applicant]
Markiewski et al., “Modulation of the anti-tumor immune response by complement,” Nature Immunology, Nov. 2008, vol. 9, No. 11, pp. 1225-1235.
[cited by applicant]
Marzano et al., “Association of Pyodenrna Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Shares Genetic and Cytokine Profiles With Other Autoinflammatory Diseases,” Medicine, Dec. 2014, vol. 93, No. 27, e187, pp…
[cited by applicant]
Marzano et al., “Hidradenitis suppurativa, neutrophilic denrnatoses and autoinflammation: what's the link?” British Journal of Dermatology, 2016, vol. 174, pp. 482-483.
[cited by applicant]
Merle et al., “Complement System Part I—Molecular Mechanisms of Activation and Regulation,” Frontiers in Immunology, Jun. 2, 2015, vol. 6, Article 262, pp. 1-30.
[cited by applicant]
Morgan et al., “Complement, a target for therapy in inflammatory and degenerative diseases,” Nature Reviews Drug Discovery, Dec. 2015, vol. 14, pp. 857-877.
[cited by applicant]
Mourvillier et al., “LB1529. Randomized, Controlled Phase 3 Study of anti-C5a Vilobelimab's Effect on Mortality in Critically III COVID-19 Patients: A Therapy for Viral Pneumonia,” Open Forum Infectious Diseases, Dec. 2…
[cited by applicant]
Navarini et al., “Neutrophilic dermatoses and autoinflammatory diseases with skin involvement-innate immune disorders,” Seminars in Immopathology, 2016, vol. 38, pp. 45-56.
[cited by applicant]
Németh et al., “Neutrophils in animal models of autoimmune disease,” Seminars in Immunology, Apr. 2016, vol. 28, No. 2, pp. 174-186.
[cited by applicant]
Nunez-Cruz et al., “Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization,” Neoplasia, Nov. 2012, vol. 14, No. 11, pp. 994-1004.
[cited by applicant]
Okroj et al., “Functional Analyses of Complement Convertases Using C3 and CS-Depleted Sera,” PLoS One, Oct. 2012, vol. 7, No. 10, e47245, pp. 1-13.
[cited by applicant]
Allegretti et al., “Targeting C5a: Recent Advances in Drug Discovery,” Current Medicinal Chemistry, 2005, vol. 12, No. 2, pp. 217-236.
[cited by applicant]
Anonymous, “Emergency Use Authorization (EUA) for Vilobeli mab (IFX-1) Center for Drug Evaluation and Research (CDER) Review,” Feb. 1, 2023, 105 pages, Retrieved from the Internet on Dec. 5, 2023; URL: <https://www.gohi…
[cited by applicant]
Anonymous, “No significant treatment effect found for IFX-1 in hidradenitis suppurativa trial,” Jun. 7, 2019, retrieved from the Internet on Nov. 12, 2019, <https://www.healio.com/dermatology/skin-care/news/online/{72df…
[cited by applicant]
Argyropoulou et al., “An Open-Label Trial to Assess the Safety of IFX-1 in Patients with Hidradenitis Suppurativa not Eligible for Adalimumab,” Aug. 4, 2017, poster (1 page).
[cited by applicant]
Beinrohr et al., “C1, MBL-MASPs and C1-inhibilor: novel approaches for targeting complement-mediated inflammation,” Trends in Molecular Medicine, 2008, vol. 14, No. 12, pp. 511-521.
[cited by applicant]
Bekker et al., “Characterization of Pharmacologic and Pharmacokinelic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Pha…
[cited by applicant]
Biedermann et al., “Regulation of T cell immunity in atopic dermatitis by microbes: the Yin and Yang of cutaneous inflammalion,” Frontiers in Immunology, Jul. 13, 2015, vol. 6, Article 353, pp. 1-9.
[cited by applicant]
Binz et al., “Engineering novel binding proteins from nonimmunoglobulin domains,” Nature Biotechnology, Oct. 2005, vol. 23, No. 10, pp. 1257-1268.
[cited by applicant]
Blok et al., “Gene expression profiling of skin and blood in hidradenitis suppurativa,” British Journal of Dermatology, 2016, vol. 174, pp. 1392-1394.
[cited by applicant]
Braun-Falco et al., “Pyoderma gangrenosum, acne, and suppuralive hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome,” Journal of the American Academy of Dermatology, Mar. 2012, vol. 66, No. …
[cited by applicant]
Brody et al., “Aptamers as therapeutic and diagnostic agents,” Reviews in Molecular Biotechnology, 2000, vol. 74, pp. 5-13.
[cited by applicant]
Buchwald et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,” Surgery, Oct. 1980, vol. 88, No. 4, pp. 507-516.
[cited by applicant]
Cannon, Joseph G., “Analog Design,” Chapter 19 in Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, vol. I: Principles and Practice, 1995, pp. 783-802.
[cited by applicant]
Carvelli et al., “Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis,” Nature, Dec. 2020, vol. 588, pp. 146-150.
[cited by applicant]
Carvelli et al., “Identification of immune checkpoints in COVID-19,” Research Square, 2020, pp. 1-30.
[cited by applicant]
Chen et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controllec by V gene combinatorial associations,” The EMBO Journal, 1995, vol. 14, No. 12, pp. 2784-2794.
[cited by applicant]
Chen et al., “Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry,” Proceedings of the National Academy of Sciences of the United States of America,…
[cited by applicant]
ClinicalTrials.gov archive, “History of Changes for Study: NCT03001622, Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa,” Study NCT03001622, Submitted Dale: Dec. 20, 2016 (v1)…
[cited by applicant]
ClinicalTrials.gov archive, “History of Changes for Study: NCT03001622, Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa,” Study NCT03001622, Submitted Dale: Mar. 20, 2017 (v3)…
[cited by applicant]
Cole et al., “Beyond lysis: how complement influences cell fate,” Clinical Science, 2003, vol. 104, pp. 455-466.
[cited by applicant]
Colman, P. M., “Effects of amino acid sequence changes on antibody-antigen interactions,” Research in Immunology, Jan. 1994, vol. 145, No. 1, pp. 33-36.
[cited by applicant]
Cugno et al., “PAPA, PASH and PAPASH Syndromes: Palhophysiology, Presentation and Treatment,” American Journal of Clinical Dermatology, Feb. 2017, vol. 18, pp. 555-562.
[cited by applicant]
Cumpelik et al., “Neutrophil microvesicles resolve gout by inhibiting C5a-medialed priming of the inflammasome,” Annals of the Rheumatic Diseases, 2016, vol. 75, No. 6, pp. 1236-1245.
[cited by applicant]
Czermak et al., “Protective effects of C5a blockade in sepsis,” Nature Medicine, Jul. 1999, vol. 5, No. 7, pp. 788-792.
[cited by applicant]
Dang et al., “Role of the complement anaphylaloxin C5a-receptor pathway in atopic dermatitis in mice,” Molecular Medicine Reports, 2015, vol. 11, pp. 4183-4189.
[cited by applicant]
D'Angelo et al., “Many Routes to an Antibody Heavy-Chain CDR3: Necessary, yet Insufficient, for Specific Binding,” Frontiers in Immunology, Mar. 2018, vol. 9, Article 395, pp. 1-13.
[cited by applicant]
Dhingra et al., “Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases,” Journal of Allergy and Clinical Immunology, Aug. 2013, vol. 132, No. 2, p…
[cited by applicant]
Drosten et al., “Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome,” The New England Journal of Medicine, May 15, 2003, vol. 348, No. 20, pp. 1967-1976.
[cited by applicant]
Dunkelberger et al., “Complement and its role in innate and adaptive immune responses,” Cell Research, 2010, vol. 20, pp. 34-50.
[cited by applicant]
During et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,” Annals of Neurology, Apr. 1989, vol. 25, No. 4, pp. 351-356.
[cited by applicant]
Finch et al., “Low-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a,” Journal of Medicinal Chemistry, 1999, vol. 42, No. 11, pp. 1965-1974.
[cited by applicant]
Gál et al., “A True Autoactivating Enzyme: Structural Insight into Mannose-Binding Lectin-Associated Serine Protease-2 Activations,” The Journal of Biological Chemistry, Sep. 30, 2005, vol. 280, No. 39, pp. 33435-33444.
[cited by applicant]
Gao et al., “Expression in
[cited by applicant]
Garcia et al., “Complement C5 Activation during Influenza A Infection in Mice Contributes to Neutrophil Recruitment and Lung Injury,” PLoS One, May 2013, vol. 8, No. 5, e64443, pp. 1-11.
[cited by applicant]
Giamarellos-Bourboulis et al., “Abstract: 003-2 I Complement activation in hidradenitis suppurativa,” Experimental Dermatology, 2017, vol. 26, Suppl. 1, pp. 3-38.
[cited by applicant]
Goodson, J. Max, “Dental Applications,” Medical Applications of Controlled Release, 1984, vol. II, Chapter 6, pp. 115-138.
[cited by applicant]
Graille et al., “CA206: PAPA, PASH, PAPASH, PsAPASH, PASS . . . des syndromes auto-inflammatoires PAS si simples,” La Revue de Medecine Interne, 2015, vol. 36, pp. A205-A206.
[cited by applicant]
Gralinski et al., “Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis,” mBio, Sep./Oct. 2018, vol. 9, No. 5, e01753-18, pp. 1-15.
[cited by applicant]
Almagro et al., “Humanization of antibodies,” Frontiers in Bioscience, Jan. 1, 2008, vol. 13, pp. 1619-1633.
[cited by applicant]
Altschul et al., “Basic Local Alignment Search Tool,” Journal of Molecular Biology, 1990, vol. 215, pp. 403-410.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, 1997, vol. 25, No. 17, pp. 3389-3402.
[cited by applicant]
Bird et al., “Single-Chain Antigen-Binding Proteins,” Science, Oct. 21, 1988, vol. 242, pp. 423-426.
[cited by applicant]
Brudno et al., “Glocal alignment: finding rearrangements during alignment,” Bioinformatics, 2003, vol. 19, Suppl. 1, pp. i54-i62.
[cited by applicant]
Bryson et al., “Prediction of Immunogenicity of Therapeutic Proteins: Validity of Computational Tools,” Biodrugs, 2010, vol. 24, Article No. 1, pp. 1-8.
[cited by applicant]
Czermak et al., “In Vitro and In Vivo Dependency of Chemokine Generation on C5a and TNF-α,” The Journal of Immunology, 1999, vol. 162, No. 4, pp. 2321-2325.
[cited by applicant]
Guo et al., “Role of C5a in Inflammatory Responses,” Annual Review of Immunology, 2005, vol. 23, pp. 821-852.
[cited by applicant]
Guo et al., “C5a, a Therapeutic Target in Sepsis,” Recent Patents on Anti-Infective Drug Discovery, 2006, vol. 1, No. 1, pp. 57-65.
[cited by applicant]
Heap et al., “Analysis of a 17-amino acid residue, virus-neutralizing microantibody,” Journal of General Virology, 2005, vol. 86, pp. 1791-1800.
[cited by applicant]
Holliger et al., ““Diabodies”: Small bivalent and bispecific antibody fragments,” Proceedings of the National Academy of Sciences of the United States of America, Jul. 1993, vol. 90, pp. 6444-6448.
[cited by applicant]
Hu et al., “Large-scale mammalian cell culture,” Current Opinion in Biotechnology, 1997, vol. 8, pp. 148-153.
[cited by applicant]
Huber-Lang et al., “Complement-Induced Impairment of Innate Immunity During Sepsis,” The Journal of Immunology, 2002, vol. 169, No. 6, pp. 3223-3231.
[cited by applicant]
Huber-Lang et al., “Role of C5a in Multiorgan Failure During Sepsis,” The Journal of Immunology, 2001, vol. 166, No. 2, pp. 1193-1199.
[cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences,” Proceedings of the National Academy of Sciences of the United States of America, Jun. 1993, vol. 90, pp. 5873-5877.
[cited by applicant]
Klos et al., “Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies,” Journal of Immunological Methods,…
[cited by applicant]
Larkin et al., “Clustal W and Clustal X version 2.0,” Bioinformatics, 2007, vol. 23, No. 21, pp. 2947-2948.
[cited by applicant]
Pawaria et al., “Complement Component C5a Permits the Coexistence of Pathogenic Th17 Cells and Type I IFN in Lupus,” The Journal of Immunology, 2014, vol. 193, No. 7, pp. 3288-3295.
[cited by applicant]
Perry et al., “New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development,” Drugs in R & D, 2008, vol. 9, No. 6, pp. 385-396.
[cited by applicant]
Qiu et al., “Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting,” Nature Biotechnology, 2007, vol. 25, No. 8, pp. 921-929.
[cited by applicant]
Riedemann et al., “Increased C5a receptor expression in sepsis,” The Journal of Clinical Investigation, Jul. 2002, vol. 110, No. 1, pp. 101-108.
[cited by applicant]
Rittirsch et al., “Functional roles for C5a receptors in sepsis,” Nature Medicine, May 2008, vol. 14, No. 5, pp. 551-557.
[cited by applicant]
Strainic et al., “Absent C3a and C5a receptor signaling into CD4+ T cells enables auto-inductive TGF-β1 signaling and induction of Foxp3+ T regulatory cells,” Nature Immunology, Feb. 2013, vol. 14, No. 2, pp. 162-171.
[cited by applicant]
Thompson et al., “Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice,” Nucleic Acids Research, 1994, vol.…
[cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Ward, Peter A., “Functions of C5a receptors,” Journal of Molecular Medicine, Apr. 2009, vol. 87, No. 4, pp. 375-378.
[cited by applicant]
Xu et al., “Interleukin-17 and its expanding biological functions,” Cellular & Molecular Immunology, 2010, vol. 7, pp. 164-174.
[cited by applicant]
Holgate et al., “Circumventing immunogenicity in the development of therapeutic antibodies,” IDrugs, 2009, vol. 12, No. 4, pp. 233-237.
[cited by applicant]
International Search Report and Written Opinion mailed Jul. 28, 2021 in corresponding International PCT Patent Application No. PCT/EP2021/061940 (10 pages).
[cited by applicant]
Oppermann et al., “Probing the Human Receptor for C5a Anaphylatoxin with Site-Directed Antibodies: Identification of a Potential Ligand Binding Site on the NH2-Terminal Domain,” The Journal of Immunology, Oct. 1993, vol…
[cited by applicant]
Pang et al., “Serum Proteomic Fingerprints of Adult Patients with Severe Acute Respiratory Syndrome,” Clinical Chemistry, 2006, vol. 52, No. 3, pp. 421-429.
[cited by applicant]
Petersen et al., “An assay for the mannan-binding lectin pathway of complement activation,” Journal of Immunological Methods, 2001, vol. 257, pp. 107-116.
[cited by applicant]
Petitclerc et al., “Pathologic Leukocyte Infiltration of the Rabbit Aorta Confers a Vasomotor Effect to Chemotactic Peptides Through Cyclooxygenase-Derived Metabolites,” The Journal of Immunology, May 1996, vol. 156, No…
[cited by applicant]
Piche-Nicholas et al., “Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fe receptor (FcRn) and pharmacokinetics,” MABS, 2018, vol. 10, No. 1, pp. 81-94.
[cited by applicant]
Prat et al., “Neutrophilic dermatoses as systemic diseases,” Clinics in Dermatology, 2014, vol. 32, No. 3, pp. 376-388.
[cited by applicant]
Proctor et al., “Transdermal Pharmacology of Small Molecule Cyclic C5a Antagonists,” Advances in Experimental Medicine and Biology, 2006, vol. 586, pp. 329-345.
[cited by applicant]
Rawal et al., “Activation of Complement Component C5: Comparison of C5 Convertases of the Lectin Pathway and the Classical Pathway of Complement,” The Journal of Biological Chemistry, Mar. 21, 2008, vol. 283, No. 12, pp…
[cited by applicant]
RCSB Protein 4UU9: Crystal structure of the human c5a in complex with MEDI7814 a neutralising antibody; retrieved from the Internet on May 26, 2023, pp. 1-5.
[cited by applicant]
Ren et al., “The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome,” Proteomics, 2004, vol. 4, No. 11, pp. 3477-3484.
[cited by applicant]
Revuz, J., “Hidradenitis suppurativa,” Journal of the European Academy of Dermatology and Venereology, 2009, vol. 23, No. 9, pp. 985-998.
[cited by applicant]
Ricardo et al., “Preclinical Evaluation of RA 101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria,” Blood, 2015, vol. 126, No. 23, p. 939.
[cited by applicant]
Ricklin et al., “The renaissance of complement therapeutics,” Nature Reviews: Nephrology, Jan. 2018, vol. 14, pp. 26-47.
[cited by applicant]
Riedemann et al., “Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition,” Clinical Immunology, 2017, vol. 180, pp. 25-32.
[cited by applicant]
Riedemann et al., “Expression and Function of the C5a Receptor in Rat Alveolar Epithelial Cells,” The Journal of Immunology, 2002, vol. 168, pp. 1919-1925.
[cited by applicant]
Riedemann et al., “Regulatory Role of C5a on Macrophage Migration Inhibitory Factor Release from Neutrophils,” The Journal of Immunology, 2004, vol. 173, pp. 1355-1359.
[cited by applicant]
Rittirsch et al., “Harmful molecular mechanisms in sepsis,” Nature Reviews Immunology, Oct. 2008, vol. 8, pp. 776-787.
[cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Sciences of the United States of America, Mar. 1982, vol. 79, pp. 1979-1983.
[cited by applicant]
Samaee et al., “Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease,” International Immunopharmacology, 2020, vol. 89, Article No. 107018, pp. 1-7.
[cited by applicant]
Sánchez-Galán et al., “Leukotriene B4 enhances the activity of nuclear factor-kB pathway through BLT1 and BLT2 receptors in atherosclerosis,” Cardiovascular Research, 2009, vol. 81, pp. 216-225.
[cited by applicant]
Sarma et al., “Complement in lung disease,” Autoimmunity, Aug. 2006, vol. 39, No. 5, pp. 387-394.
[cited by applicant]
Saudek et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,” The New England Journal of Medicine, Aug. 31, 1989, vol. 321, No. 9, pp. 574-579.
[cited by applicant]
Schatz-Jakobsen et al., “Structural and functional characterization of human and murine C5a anaphylatoxins,” Acta Crystallographica Section D Biological Crystallography, Jun. 2014, vol. 70, Pl. 6, pp. 1704-1717.
[cited by applicant]
Schwaeble et al., “Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury,” Proceedings of the National Academy of Sciences of…
[cited by applicant]
Sefton, Michael V., “Implantable Pumps,” CRC Critical Reviews in Biomedical Engineering, 1987, vol. 14, No. 3, pp. 201-240.
[cited by applicant]
Slade et al., “Hidradenitis suppurativa: pathogenesis and management,” British Journal of Plastic Surgery, 2003, vol. 56, No. 5, pp. 451-461.
[cited by applicant]
Smith, Kristen, “If at first you don't succeed . . . ,” Jul. 2019; retrieved from the Internet on Nov. 12, 2019 <https://www.ddn-news.com/index.php?newsarticle=13478> (2 pages).
[cited by applicant]
Song et al., “C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury,” International Immunopharmacology, 2018, vol. 59, pp. 12-20.
[cited by applicant]
Souza et al., “APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury,” British Journal of Pharmacology, 2005, vol. 145, N…
[cited by applicant]
Strainic et al., “Absent C3a and C5a receptor signaling into CD4+ T cells enables auto-inductive TGF-B1 signaling and induction of Foxp3+ T regulatory cells,” Nature Immunology, Feb. 2013, vol. 14, No. 2, pp. 162-171.
[cited by applicant]
Strieter et al., “Cytokine-induced Neutrophil-derived Interleukin-8,” American Journal of Pathology, Aug. 1992, vol. 141, No. 2, pp. 397-407.
[cited by applicant]
Sun et al., “Inhibition of Complement Activation Alleviates Acute Lung Injury Induced by Highly Pathogenic Avian Influenza H5N1 Virus Infection,” American Journal of Respiratory Cell and Molecular Biology, Aug. 2013, vo…
[cited by applicant]
Sun et al., “Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys,” Clinical Infectious Diseases, 2015, vol. 60, No. 4, pp. 586-595.
[cited by applicant]
Tagami, “Recent topics in sterile pustular dermatoses,” Japanese Journal of Inflammation, 1986, vol. 6, No. 1, pp. 5-14. [English Abstract].
[cited by applicant]
Takahashi et al., “The mannose-binding lectin: a prototypic pattern recognition molecule,” Current Opinion in Immunology, 2006, vol. 18, pp. 16-23.
[cited by applicant]
Tang et al., “Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia,” Journal of Thrombosis and Haemostasis, 2020, vol. 18, pp. 844-847.
[cited by applicant]
Tang et al., “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy,” Journal of Thrombosis and Haemostasis, 2020, vol. 18, pp. 1094-1099.
[cited by applicant]
Taylor, Phil, “InflaRx flallines after skin disease drug flops in midstage trial,” pharmaphorum, Jun. 6, 2019; retrieved from the Internet on Nov. 12, 2019 <hllps://pharmaphorum.com/news/inflarx-flallines-skin-disease-d…
[cited by applicant]
Ternowitz et al., “Methotrexate Inhibits the Human C5a-Induced Skin Response in Patients with Psoriasis,” The Journal of Investigative Dermatology, Aug. 1987, vol. 89, No. 2, pp. 192-196.
[cited by applicant]
Tesar et al., “Avacopan in the treatment of ANCA-associated vasculitis,” Expert Opinion on Investigational Drugs, 2018, vol. 27, No. 5, pp. 491-496.
[cited by applicant]
Treat et al., “Liposome Encapsulated Doxorubicin Preliminary Results of Phase I and Phase II Trials,” Liposomes in the Therapy of Infectious Diseases and Cancer, Lopez-Berestein and Fidler (eds.), 1989, pp. 353-365.
[cited by applicant]
Tzanetakou et al., “Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial,” JAMA Dermatology, 2016, vol. 152, No. 1, pp. 52-59.
[cited by applicant]
UniProtKB P01031: C05_Human; retrieved from the Internet on May 26, 2023 (13 pages).
[cited by applicant]
UniProtKB P05231: IL6_Human; retrieved from the Internet on May 26, 2023 (12 pages).
[cited by applicant]
USBiological Life Sciences Certificate of Analysis for Antibody Clone No. 7H110 (Mouse Anti-Human COBB Antibody), Date of Manufacture: May 17, 2017 (1 page).
[cited by applicant]
Verdolini et al., “Metformin for the treatment of hidradenitis suppurativa: a little help along the way,” Journal of the European Academy of Dermatology and Venereology, 2013, vol. 27, No. 9, pp. 1101-1108.
[cited by applicant]
Vlaar et al., “Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial,” The Lancet Rheumat…
[cited by applicant]
Wallis, Russell, “Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway,” Immunobiology, 2007, vol. 212, pp. 289-299.
[cited by applicant]